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ABSTRACT
The median age for total hip arthroplasty (THA) is 
over 70 years with the corollary that many individuals 
have multiple multimorbidities. Despite the predicted 
improvement in quality of life, THA might be denied even to 
those with low levels of multimorbidity.
Objective To evaluate how pre- existing levels of 
multimorbidity influence the likelihood and timing of THA.
Setting Longitudinal record linkage study of a UK sample 
linking their primary care to their secondary care records.
Participants A total of 28 025 patients were included, 
based on the recording of the diagnosis of hip 
osteoarthritis in a national primary care register, Clinical 
Practice Research Datalink. Data were extracted from 
the database on background health and morbidity status 
using five different constructs: Charlson Comorbidity Index, 
Electronic Frailty Index and counts of chronic diseases 
(from list of 17), prescribed medications and number of 
primary care visits prior to recording of osteoarthritis.
Outcome measures The record of having received a 
THA as recorded in the primary care record and the linked 
secondary care database: Hospital Episode Statistics.
Results 40% had THA: median follow 10 months (range 
1–17 years). Increased multimorbidity was associated with 
a decreased likelihood of undergoing THA, irrespective 
of the method of assessing multimorbidity although the 
impact varied by approach.
Conclusion Markers of pre- existing ill health influence 
the decision for THA in the elderly with end- stage hip 
osteoarthritis, although these effects are modest for 
indices of multimorbidity other than eFI. There is evidence 
of this influence being present even in people with 
moderate decrements in their health, despite the balance 
of benefits to risk in these individuals being positive.
INTRODUCTION
Total hip arthroplasty (THA) is a highly cost- 
effective procedure for hip osteoarthritis 
(OA).1 The mean age at surgery in many 
Organisation for Economic Co- operation and 
Development (OECD) member countries is 
currently around 70 years,2 and consequently, 
many patients being considered for THA 
will have multiple comorbidities.3 Our anec-
dotal experience, reinforced by the patients 
consulted prior to this research, was that 
pre- existing morbidities raise concerns 
about operative risk and hence deter surgery 
thereby limiting access to those who may 
otherwise benefit. Balancing risks and bene-
fits of surgical procedures, for example, 
invasive cardiac procedures, has been well 
discussed for such potentially life- threatening 
disorders.4 There is however very little 
evidence to guide healthcare professionals 
on the risks and benefits of THA in elderly 
patients with multimorbidity but who have 
severe limitation of quality of life.5 6 In one 
report recently published from a tertiary care 
centre from the USA, background comor-
bidity was linked to both an increased risk of 
complications and a poorer outcome.7 The 
concern, though, is that those with relatively 
modest background levels of multimorbidity 
may be excluded from surgery. Our objective 
was to determine, using a national primary 
care database, how levels of pre- existing 
Strengths and limitations of this study
 ► National sample of older patients recorded in prima-
ry care with newly reported osteoarthritis of the hip.
 ► Multidimensional approach to assessing their con-
current morbidity and health status.
 ► Linkage to national hospital records to assess re-
ceipt of surgery.
 ► The challenge of using such routine data sources is 
to quantify the completeness and accuracy of diag-
nostic and treatment records.
 ► Not able to assess impact on multimorbidity on re-
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In brief, we undertook a cohort study analysing routinely 
collected data gathered from the UK’s Clinical Practice 
Research Datalink (CPRD) (ISAC approval number 
17_024R).8 This database of longitudinal primary care 
records was interrogated to identify elderly patients 
(aged 65 years and over) with a recorded diagnosis of 
hip OA. From these individuals, data from their CPRD 
record were used to extract information on their general 
health and disease status from which five approaches to 
scoring their multimorbidity were derived. Patients were 
then followed up to identify those recorded as receiving 
a THA. CPRD records were linked with records from the 
English Index of Multiple Deprivation (IMD) and the 
Office for National Statistics mortality dataset for data on 
secio- economic status and death.
Subjects
These were 28 025 patients who had been diagnosed 
with hip OA according to electronic medical records 
in the CPRD GOLD database (see online supplemental 
appendix 1) between 1 January 1995 and 30 April 2014. 
The diagnosis of hip OA was based on being recorded with 
at least one from a list of relevant READ codes (online 
supplemental appendix 2).9 A validation exercise was 
performed, in which clinical and radiographic data were 
obtained on a small subsample of 119 of these patients. 
Based on these detailed data, 88% were confirmed as 
having hip OA, which showed a sufficiently high level of 
diagnostic accuracy against accepted clinical criteria.10
Multimorbidity markers
Information extracted from the longitudinal primary 
care records was used to score patients into different 
categories of five separate approaches to assessing their 
background morbidity and health at the time of the first 
recording of hip OA. The spectrum of measures aimed to 
cover: (1) specific risk scores accepted as predictive for 
postsurgical morbidity, (2) more generalised scores of 
health and function and (3) scores of healthcare utilisa-
tion. The specific scores used were:
1. Simple count of ever mention of the 17 chronic 
disorders included in the Quality and Outcomes 
Framework11 (online supplemental appendix 3), a 
scheme to ensure maximal primary care compliance 
with recording chronic disorders.
2. Charlson Comorbidity Index (CCI) based on the cu-
mulative burden of its components over the previous 5 
years. The CCI is a well- accepted measure of perioper-
ative and postoperative morbidity12
3. Electronic Frailty Index (eFI), a validated tool that 
aims to score frailty based on the number of different 
‘deficits’ mentioned in the primary care record across 
a large number of health domains.13
4. Count of the number of different individual medica-
tions in the previous 12 months via CPRD GOLD pre-
scription data.
5. Count of consultation events with primary care in the 
previous 12 months as a measure of health services 
burden.
Follow-up
Patients were then followed up using their CPRD record 
to identify those where there was a record of receiving 
THA based on relevant codes in CPRD14 by January 2015. 
As recording of THA may not be complete in CPRD, we 
also considered the alternative source ascertainment of 
THA based on linkage of CPRD records to the anony-
mised data from the national Hospital Episode Statistic 
(HES) dataset. HES linkage is only available for England; 
not all general practices in CPRD permitted linkage. We 
therefore conducted a sensitivity analysis (see further) 
using the HES data.
Analysis
The analysis was directed towards assessing the relation-
ship between the different categories of each of the multi-
morbidity scoring systems. Thus, we assessed both the 
cumulative incidence and the time to event of receiving 
a THA following the diagnosis of hip OA in the primary 
care record. There was a concern that in some cases the 
diagnostic label of hip OA may have been applied by the 
primary care physician once the decision to refer for 
surgery had been made. Thus, an arbitrary decision was 
made to exclude those who had surgery within 30 days 
from the diagnosis date as coded in the record. For each 
of the five approaches to scoring morbidity, patients were 
divided into four categories of increasing severity. The 
overall incidence of THA per 100 patient years was calcu-
lated for each category. The association between multi-
morbidity categories and the likelihood of THA was then 
investigated using Fine and Gray competing risk analysis 
models15 with death being considered a competing event. 
The models are presented as morbidity- specific HRs with 
95% CIs. The lowest multimorbidity category was defined 
as the referent category. Univariate and then multivar-
iate models, adjusted for age, sex, region of the UK and 
calendar year of diagnosis, were conducted. We addressed 
the potential bias of the incompleteness of THA in the 
CPRD record. To assess this, we undertook a sensitivity 
analysis in the subset of practices with HES linkage using 
HES as a source of THA data.
Patient and public involvement
This research was funded by the National Institute for 
Health Research Research for Patient Benefit scheme, 
which has an absolute requirement that there is patient 
and public involvement in all relevant stages of the 
research. The research question had been originally 
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for Research in Hip and Knee Arthroplasty’, and this 
was followed by a survey of members of the Keele PPI 
panel: Research Users Group (RUG). We then tested 
the suggested questions with the group and received 
very positive feedback. One of the RUG members (CW), 
herself a patient with direct experience of the target 
of the research, then became an active member of the 
research team, participated in all the meetings and 
advised on the design including the questions that should 
be asked during the analysis stage. As part of the dissem-
ination phase, Keele PPI group organised a round table 
event attended by the lead authors where the results were 
discussed and guidance given on how those members of 
the public who were present wished to see disseminated.
RESULTS
In all, 28 025 patients aged over 65 years had been diag-
nosed with hip OA in their CPRD GOLD records between 
1 January 1995 and 30 April 2014. Their mean age was 75 
years and 62% were female. The details of their demo-
graphic characteristics are shown in table 1.
The distributions of morbidity data using the allocation 
of categories for the patients, at the time of first recording 
of their hip OA, are shown in table 2. The CCI scores 
showed that two- thirds had a score of 0, a similar propor-
tion to those who had one or less other chronic disorder. 
The proportion of subjects in each category of increasing 
score showed broadly similar trends for the three ‘count’ 
approaches of assessing morbidity. The frailty scores 
based on the eFI showed that only around 6% could be 
categorised as being ‘moderately’ or ‘severely’ frail.
On follow- up (figure 1), 11 413 subjects had a THA at 
some stage. As discussed previously, we excluded 465 who 
had surgery within 30 days from the diagnosis date. Of 
the remainder, 10 948 (39.7%) received a THA during 
the follow- up period with a median interval of just under 
10 months, range 1 month to 17 years. The overall inci-
dence of THA during the period of observation was 
11.5/100 person years, that is, just over 10% per year. The 
THA rates by morbidity category are shown in table 3. 
In this crude analysis, there was variation in the rela-
tionship between the scores of the different measures of 
morbidity on whether or not a patient had surgery during 
follow- up. All the measures apart from the Charlson 
score showed a trend of decreasing surgery rates with 
increasing morbidity: the trend was steeper with eFI and 
only modest with the other measures. There was no trend 
of increasing surgery with the Charlson score.
The associations between each morbidity measure and 
time to surgery are shown in table 4. The cumulative inci-
dence of surgery over time is also displayed graphically 
for each of the measures of morbidity in online supple-
mental figures 1-5. These results show a marked trend of 
decreasing likelihood of surgery with increasing levels 
of morbidity, however defined. The graphs show that 
the decreased likelihood of surgery is concentrated in 














Gender Male 10 662 38.0
Female 17 363 62.0











Most deprived 1696 9.4
*No record of BMI in 5681.
†IMD data missing in 9987 as only available in England and on 
patients with linked records.
BMI, body mass index; IMD, Index of Multiple Deprivation.
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the earliest period of follow- up. Although the decreased 
occurrence of surgery was not unexpected, the reduc-
tion in surgery rates was observed even in those with the 
least increase in their morbidity status above ‘baseline’. 
Thus, for example, those who were only ‘mildly’ frail or 
had a CCI of 1 were 23% and 16% less likely, respectively, 
to have surgery. Adjustment for age and gender made 
little difference to the results suggesting that it was the 
morbidity and not age that explains the data.
DISCUSSION
This paper provides a snapshot of the levels of background 
morbidity and health utilisation on large national cohort 
of elderly patients newly presenting to their general prac-
titioner with hip OA. Not surprisingly given concerns 
about operative risk, the results showed that the greater 
the pre- existing morbidity, the longer the time to surgery. 
However, this influence on time to surgery is observed 
even in those with a low degree of multimorbidity. In 
this analysis, those who were just mildly frail had almost 
a quarter lower rate of surgery. Whether multimorbidity 
should influence decision for elective hip surgery has been 
debated given the relative lack of influence on long term 
mortality.16 In a companion paper, the influence of multi-
morbidity on the outcomes of THA is examined, using 
the same UK primary care derived population, with the 
outcomes of improvement in pain, function and quality 
of life, and the rate of complications, revision surgery and 
death. the benefits of surgery in terms of quality of life. 
The results showed that benefits of surgery were substan-
tial regardless of baseline morbidity, while the increase in 
Figure 1 Flow chart of participants (see attached file). OA, 
osteoarthritis; THA, total hip arthroplasty.
Table 3 Crude incidence of total hip arthroplasty by morbidity measure
Morbidity scale Category THA (N) PYR
Incidence
/100PYR 95% CI
Charlson Comorbidity Index 0 7878 64 676 12.2 11.9 to 12.4
1 1160 11 729 9.9 9.3 to 10.5
2 1115 10 096 11.0 10.4 to 11.7
3+ 795 8628 9.2 8.6 to 9.9
Count of chronic diseases
  
0 4248 34 744 12.2 11.9 to 12.6
1 3631 30 613 11.9 11.5 to 12.2
2 1955 17 482 11.2 10.7 to 11.7
3+ 1114 12 289 9.1 8.5 to 9.6
Count of medications prescribed 0–4 4674 38 337 12.2 11.8 to 12.5
5–7 2911 24 489 11.9 11.5 to 12.3
8–12 2421 22 576 10.7 10.3 to 11.2
13+ 942 9726 9.7 9.1 to 10.3
Count of contacts with primary care 0–7 4946 42 662 11.6 11.3 to 11.9
8–11 2559 21 483 11.9 11.5 to 12.4
12–17 1939 16 902 11.5 11.0 to 12.0
18+ 1504 14 080 10.7 10.1 to 11.2
Electronic Frailty Index 0–4 8373 69 541 12.0 11.8 to 12.3
5–8 2249 21 349 10.5 10.1 to 11.0
9–12 303 3839 7.9 7.0 to 8.8
13+ 23 399 5.8 3.4 to 8.1
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risk of complication or death was modest, even for those 
with the highest levels of baseline morbidity.17
Strengths and limitations
The population studied was derived from a national 
population database, CPRD GOLD, and provided a 
representative sample of patients in primary care with OA 
of the hip.8 A primary care data set is also the only option 
for providing information on the levels of morbidity at 
the time of recording the hip diagnosis. These could 
then be analysed prospectively to evaluate the relation-
ship between morbidity and the likelihood of surgery. 
Multimorbidity is a concept with no single measure that is 
perfect.18 We used a broad range of measures, each iden-
tifying a different concept of multimorbidity that might 
have influenced surgical decision making.
There are a number of limitations that must be consid-
ered before interpreting the results further.
These data are based on the primary care recording of OA 
of the hip in this electronic dataset. There were likely to be 
errors both in terms of under- reporting of all cases and diag-
nostic inaccuracy in those who were included. We (DY, GP 
and KPJ) have previously reported on a retrospective analysis 
of the presence of codes for hip OA specifically, and OA in 
general, in patients who had a THA recorded in CPRD.19 
In that analysis, there was substantial under- reporting of hip 
OA when relying on a specific code of hip OA, although 
the under- recording was lower when allowing the primary 
care to mention OA in any joint. The latter would have 
been too non- specific for the current analysis. By contrast 
(as mentioned previously), the level of diagnostic inaccuracy 
in those who were recorded as having hip OA, based on a 
detailed clinical review of a sample of cases, was low.10 We 
also have no data on laterality so we had to assume that the 
side of the recorded OA was the same side as the surgery.
The major aim of the analysis was to study the time to 
surgery following the recording of the diagnosis of hip OA. 
Patients attending their primary care physician with hip pain 
or other relevant symptom may have only been recorded 
as having OA once a decision to refer for surgery had been 
made. Indeed, given the potential for under- reporting of OA 
of the hip, it is perhaps more likely that the OA label may 
have been made on those with more definite and severe OA. 
We also made the assumption that the side of diagnosis of 
hip OA was the side that was operated on.
These points illustrate the challenges in relying on 
administrative databases from primary care to identify a 
complete population of cases. Thus, our results on the 
relationship between multimorbidity and THA can only 
refer to those with a hip OA code.
We are unable to separate from our data set the contri-
bution that baseline multimorbidity made between the 
decision by primary care to refer for an orthopaedic opinion 
Table 4 THA surgery rates by morbidity status






(95% CI) Adjusted HR* (95% CI)
Charlson Comorbidity 
Index
0 18 303 2279 7878 Ref Ref
1 3202 630 1160 0.79 (0.75 to 0.84) 0.84 (0.79 to 0.89)
2 3261 596 1115 0.78 (0.74 to 0.84) 0.81 (0.76 to 0.87)
3+ 2794 656 795 0.63 (0.58 to 0.68) 0.65 (0.60 to 0.70)
Count of chronic diseases 0 9228 1142 4248 Ref Ref
1 8802 1231 3631 0.90 (0.86 to 0.94) 0.91 (0.87 to 0.95)
2 5339 881 1955 0.80 (0.76 to 0.84) 0.81 (0.77 to 0.86)
3+ 4191 907 1114 0.57 (0.53 to 0.61) 0.59 (0.55 to 0.63)
Count of medications 0–4 10 250 1206 4674 Ref Ref
5–7 7234 1111 2911 0.89 (0.85 to 0.93) 0.92 (0.88 to 0.97)
8–12 6857 1169 2421 0.78 (0.74 to 0.82) 0.81 (0.77 to 0.86)
13+ 3219 675 942 0.64 (0.59 to 0.68) 0.67 (0.62 to 0.72)
Count of contacts with 
primary care
0–7 11 790 1570 4946 Ref Ref
8–11 6272 866 2559 1.00 (0.95 to 1.04) 1.02 (0.97 to 1.07)
12–17 5097 825 1939 0.92 (0.88 to 0.97) 0.95 (0.91 to 1.01)
18+ 4401 900 1504 0.82 (0.77 to 0.87) 0.85 (0.81 to 0.91)
Electronic Frailty Index 0–4 19 102 2596 8373 Ref Ref
5–8 6900 1157 2249 0.75 (0.71 to 0.78) 0.77 (0.74 to 0.81)
9–12 1391 354 303 0.48 (0.43 to 0.54) 0.52 (0.47 to 0.59)
13+ 167 54 23 0.31 (0.20 to 0.46) 0.34 (0.22 to 0.51)
*Age, gender, region and year of diagnosis.















pen: first published as 10.1136/bm






6 Ferguson R, et al. BMJ Open 2021;11:e046713. doi:10.1136/bmjopen-2020-046713
Open access 
from that made in secondary care as to whether to have surgery. 
Although in practice such a separation may be hard to 
interpret as the referring primary care physician may 
influence both the patient and the orthopaedic surgeon 
in their decision. In theory, referral data are captured in 
UK primary care, but in practice, this was missing for most 
of the patients. We are unable to address from these data 
at what stage and what were the predominant influences 
that lead to a greater reluctance for surgery.
Any study such as this reflects the decisions made in rela-
tion to factors operating in the UK health system at that 
point in time. Views about the need for surgery and secular 
changes in resource availability might have influenced our 
results. We therefore adjusted for year of diagnosis and 
found no difference. However, it is interesting to see, for 
example, how the recent COVID-19 epidemic might influ-
ence surgical decision making currently. Indeed, the CCI is 
being modified to collect such information.20
CPRD provides access to the detailed primary care record 
that permitted the unique opportunity to derive the multi-
morbidity scores analysed in this study. Given the routine 
nature of the data gathering, there is scope for errors in the 
accuracy of the individual components, and the limitations 
of CPRD are well described.8 Multimorbidity as assessed by 
our scores is not static. We examined the influence of the 
scores at the time of first recording of hip OA. Apart from 
the healthcare utilisation type scores (drug counts and 
primary care visits), the scores were based on accumula-
tion of multimorbidities (over 5 years for CCI and ever for 
eFI and disease count) to the time of diagnosis. Given the 
median time between primary care recording and surgery 
was under a year, we suggest that these scores are unlikely to 
have changed to any important extent.
The crude incidence rates of surgery show a decreasing 
trend with increasing level of morbidity. These trends 
in rate of surgery were more pronounced when using a 
survival analysis. In addition, a separate question regarding 
those for whom the decision for surgery had been made is 
whether there was any influence of health pre- operative 
health status on delay to surgery. This analysis suggests 
that the interval between diagnosis and surgery was, if 
anything, slightly shorter in those with worse health (see 
online supplemental table 1). One explanation for this 
somewhat paradoxical result is that once the decision had 
been made to have surgery in the more ‘at risk groups’, 
then there was no reason to have any additional delay.
We used CPRD GOLD as our source of data on THA. THAs 
would be recorded in CPRD GOLD providing the informa-
tion is fed back to patients’ general practitioners by surgeons 
and the information is coded in their medical records.
In the UK, data on THAs funded by the National 
Health Service are also available from HES, which can be 
linked to CPRD. However, HES does not cover Scottish, 
Northern Ireland or Welsh patients, and also linkage to 
HES was not available for all practices; a link was only 
possible for just under 17 000 of our cohorts. We did 
undertake a sensitivity analysis (online supplemental 
table 2) using that subset. Although the total numbers 
were lower, the morbidity distributions were similar as, 
reassuringly, were the relationships with the likelihood of 
surgery in this subset to the whole dataset.
Finally, there are key confounders, which might explain 
the results. Thus, both BMI and smoking may be key contrib-
utors to the decision as to whether a patient with OA has 
surgery. CPRD GOLD records are incomplete in regard 
to these variables, and there is also concern of overadjust-
ment. BMI might be the major predictor of the likelihood of 
surgery and should be examined. BMI data were available in 
22 344 (79.8%) of the cohort but at varying times in relation 
to the record of OA. Given the lack of data of BMI at the 
time of OA diagnosis, it was not considered appropriate to 
adjust for this in the subset with a BMI record. As a check 
of the impact of excluding BMI as a confounder, we found 
only a very modest relationship between BMI category and 
surgery (data not shown) and did not alter the associations 
with morbidity in that subset.
Although we have demonstrated in a companion paper 
that coexisting morbidity did not constrain clinical benefit,17 
this does not capture all the reasons why surgery does not 
occur. Patients supported by their healthcare professionals 
may judge that their other health issues are so predominant 
to increase the reluctance for surgery despite the possible 
benefit. When we presented the results of this study to our 
patient partners, this was not their expressed view, but this 
requires further investigation.
In conclusion, modest multimorbidity does influence the 
timing of when patients undergo THA in the UK, despite 
evidence that the benefits in such groups outweigh the 
harms.
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